Date |
Company |
Amount |
Funding type |
Investors |
Therapeutic area |
Type of Information |
2014-09-17 |
MGB Biopharma (UK) |
£4.0 million ($6.4 million - €5.02 million) |
financing round |
Archangels (UK), Barwell PLC (UK), TRI Cap (UK), the Scottish Investment Bank (UK) |
Infectious diseases |
Financing round |
2014-09-17 |
Affimed (Germany) |
$ 56 million |
IPO |
|
Cancer - Oncology |
IPO |
2014-09-16 |
Inventiva (France) Curie-Cancer (France) |
|
grant |
ANR - French National Research Agency (France) |
Cancer - Oncology - Respiratory diseases |
Grant |
2014-09-16 |
Nordic Nanovector (Norway) |
NOK 50 million ($7,8 million - €6 million) |
private placement |
HealthCap, existing shareholders, new institutional and professional investors |
Cancer - Oncology |
Private placement |
2014-09-15 |
Morphosys (Germany) |
up to € 1 million |
grant |
German Ministry of Education and Research (BMBF) (Germany) |
|
Grant |
2014-09-12 |
Osmia Pharmaceutical (Sweden) |
|
IPO |
|
Veterinary medicine - Cancer - Oncology |
IPO |
2014-09-11 |
Mimetas (The Netherlands) |
$1.6 million |
grant |
|
|
Grant |
2014-09-10 |
Beta-O2 (Israel) |
$0.5 million |
grant |
JDRF (USA - NY) |
Metabolic diseases - Regenerative medicine |
Grant |
2014-09-10 |
Alize Pharma (France) |
€ 5 million |
financing round |
Bpifrance (France), Octalfa (France), Sham Innovation Sante (France), CEMA (Canada), TAB Consulting (France) |
Metabolic diseases - Rare diseases |
Financing round |
2014-09-10 |
AM-Pharma (The Netherlands) |
€12.2 million |
financing round |
Gilde Healthcare (The Netherlands) - Ysios Capital Partners (Spain) - Kurma Biofund (France) - Abbvie (USA) - BB Biotech Ventures (Switzerland) - Idinvest Partners (France) - Inventages Venture Capital (UK-Switzerland-New Zealand-Bahamas) |
Inflammatory diseases |
Financing round |
2014-09-09 |
Poxel (France) |
€10 million |
series B financing round |
Edmond de Rothschild Investment Partners - EdRIP (France) InnoBio (France) Omnes Capital - formerly Crédit Agricole Private Equity (France) |
Metabolic diseases |
Series B financing round |
2014-09-09 |
Therametrics, formerly known as Mondobiotech (Switzerland) |
CHF 20 million (€16.5 million) |
private placement |
Fin Posillipo (Italy), existing and new shareholders |
Technology - Services |
Capital increase |
2014-09-09 |
F2G (UK) |
£1.4 million |
grant |
Biomedical Catalyst Fund (UK) |
Infectious diseases |
Grant |
2014-09-07 |
Cardiorentis (Switzerland) |
€ 45 million |
fundraising |
HealthCare Royalty Partners (USA) |
Cardiovascular diseases |
Fundraising |
2014-09-04 |
Biocartis (Belgium) |
€ 64.5 million |
financing round |
Johnson & Johnson Development Corporation, a J&J company (USA - NJ) , Hitachi Chemical Corporation (Japan), PMV Tina Fund (Belgium), undisclosed family offices |
Diagnostic - Cancer - Oncology - Infectious diseases |
Financing round |
2014-09-04 |
MyCartis (Belgium) |
€ 15 million |
financing round |
RMM, Valiance (UK), Biover II (Belgium) |
Diagnostic |
Financing round |
2014-09-04 |
Biomay (Austria) |
€2.8 million |
capital increase |
existing shareholders |
Allergic diseases |
Capital increase |
2014-09-03 |
4SC AG (Germany) |
€500,000.00 |
fundraising |
Yorkville Advisors LLC (USA) |
|
Fundraising |
2014-09-02 |
Quantum Genomics (France) |
260 K€ |
fundraising |
Bpifrance (France) |
Cardiovascular diseases |
Fundraising |
2014-09-02 |
Affimed (Germany) |
$29.7 million (€22.2 million) |
series E financing round, loan |
|
Cancer - Oncology |
Financing round |